SAVA240705P9000
- 0.02
- 0.000.00%
Cassava Sciences Newsroom
Top 5 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go u
FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; Once-Monthly Infusions Reduced Amyloid Plaques By...
FDA Approves Kisunla For Early Symptomatic Alzheimer's Disease; Phase 3 Study Shows Kisunla Slowed Cognitive And Functional Decline By Up To 35% And Reduced Risk Of Disease Progression By Up To 39%; O
Cassava Forms Committee After US Probe, Researcher Fraud
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
Why Cassava Sciences Stock Is Sinking Today
Cassava Sciences Down Another 3% as SEC Provides Update on Simufilam Probe
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Cassava Sciences (NASDAQ:SAVA) has engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employ
JonesTrading Downgrades Cassava Sciences(SAVA.US) to Hold Rating
JonesTrading analyst Soumit Roy downgrades $Cassava Sciences(SAVA.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 22.6% and a total average return of -13.9% over th
Cassava Sciences Cut to Hold From Buy by Jones Trading
Cassava Sciences Cut to Hold From Buy by Jones Trading
Jones Trading Downgrades Cassava Sciences to Hold
Jones Trading analyst Soumit Roy downgrades Cassava Sciences (NASDAQ:SAVA) from Buy to Hold.
Express News | Cassava Sciences Inc : Jonestrading Cuts to Hold Rating
Express News | Cassava Sciences Shares Drop About 12% as Co Forms Panel After Probes by U.S. Regulators
Express News | Cassava Sciences Shares Slump 16% Premarket After Co Says Engaging With DOJ and SEC in Connection With Probe Into Co, Senior Employees
Express News | Cassava Sciences: Internal Investigation Determined Some Information Could Have Been Used to Unblind Wang Him to Some Phase 2B Study Participants
Express News | Cassava Sciences: Conducting Two Randomized, Placebo-Controlled Phase 3 Clinical Trials Oral Simufilam in Patients With Mild-to-Moderate Alzheimer’s
Express News | Cassava Sciences Inc: Based Committee Review of Internal Investigation to Date, Supplementing Its Prior Disclosures Regarding Phase 2B Study
Express News | Cassava Sciences Inc: Internal Investigation Also Evaluating Information Contained in DOJ Indictment of Hoau-Yan Wang
Express News | Cassava Sciences Inc -Board Empowered Ad Hoc Investigation Committee to Direct an Investigation of the Information Provided by the SEC
Express News | Cassava Sciences : Engaging With DOJ and SEC in Connection With Ongoing Investigations Into Co and Two Senior Employees
Cassava Sciences Engages With DOJ And SEC Amid Ongoing Investigations; Company Board Empowers Ad Hoc Committee For Internal Investigation Based On SEC Findings
DOJ Indicts Dr. Hoau-Yan Wang For Allegedly Defrauding NIH With False Research Data; Wang Previously Served As Scientific Advisor To Cassava, Conducted Key Bioanalysis For Simufilam Phase 2b Study, An